enGene hosts Aug 11 virtual KOL event on NMIBC market research insights

enGene Therapeutics Inc.

Virtual KOL event held August 11, 2026 to discuss emerging non-muscle invasive bladder cancer (NMIBC) market research.
Presentation filed as Exhibit 99.1; company positioned as non-viral genetic medicine developer.
No clinical data, financial results, or guidance disclosed in the filing; exhibit contains only title and disclaimers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.